Research programme: inflammatory bowel disease - Androclus Therapeutics

Drug Profile

Research programme: inflammatory bowel disease - Androclus Therapeutics

Alternative Names: AT-005; AT-007

Latest Information Update: 20 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Androclus Therapeutics
  • Class Peptides
  • Mechanism of Action Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Crohn's disease; Ulcerative colitis

Most Recent Events

  • 20 Sep 2006 This programme is still in active development
  • 22 Jun 2005 Preclinical trials in Crohn's disease in USA (PO)
  • 22 Jun 2005 Preclinical trials in Ulcerative colitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top